Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 1997

View Archived Issues

FTC gives go-ahead for Behring Diagnostics-Dade merger

New antitumor agents discovered at Sagami

Squalene synthase inhibitors in development at Sankyo

Substance P antagonists discovered at Kotobuki

Nonpeptide CRF1 antagonist reduces cerebral infarction in rats

Phase IV trial of Redux

Lovenox superiority established in ESSENCE trial

Roche: 1997 half-year highlights

Laserscope receives approvable letter from FDA

InSite Vision initiates phase II study of ISV-120

Celgene receives patent for SelCID

Theratope vaccine advances to phase III trials

U.S. patent allowed for erectile dysfunction therapy

Millennium reports discovery of new MAD-related proteins

Visualine II receives FDA clearance for marketing

Advisory committee will meet to discuss Synovir NDA

Triangle Pharmaceuticals: Q2 1997 highlights

Non-parenteral insulin formulations for treating IDDM

TNF-alpha inhibitors reported by Centocor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...